Clincierge Releases Study on Patient Experience in Clinical Trials
Clincierge has released "Voice of the Patient," a research report examining the patient experience in clinical trials of rare diseases.
Findings in "Voice of the Patient" include:
- Sixty-two percent of patients and 59% of caregivers say travel stopped them from participating in a clinical trial, while 42% of patients and 47% of caregivers say financial issues stopped them from participating.
- Of patients who participated in a clinical trial, 68% say travel in previous clinical trials has been "difficult" and 95% say they "seriously" considered dropping out because of challenges associated with travel.
- Sixty-five percent of patients say receiving reimbursements made it "a lot" easier to remain in a clinical trial. However, one in three say it has taken a month or more to receive reimbursement while participating in a trial.
Read more about the report here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
